Maintenance of head and neck tumor on-chip: Gateway to personalized treatment?

Future Science OA

Volumn 3, Issue 2, 2017, Pages

  Bower, Ruth ^a   Green, Victoria L ^a   Kuvshinova, Elena ^b   Kuvshinov, Dmitriy ^a   Karsai, Laszlo ^c   Crank, Stephen T ^c   Stafford, Nicholas D ^a   Greenman, John ^a  

^a UNIVERSITY OF HULL   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c HULL ROYAL INFIRMARY   (United Kingdom)

Author keywords

Head and neck cancer; Microfluidic; Tissue culture; Tumor

Indexed keywords

BIOLOGICAL MARKER; PROPIDIUM IODIDE; TRYPAN BLUE;

ARTICLE; BIOCHIP; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CELL CULTURE MONITORING; CELL DEATH; CELL PROLIFERATION; CELL VIABILITY; CHEMORADIOTHERAPY; COMPUTATIONAL FLUID DYNAMICS; CONTROLLED STUDY; DISSOCIATION; FLOW CYTOMETRY; FLUID FLOW; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LAB ON A CHIP; LAMINAR FLOW; MATHEMATICAL MODEL; MICROELECTROMECHANICAL SYSTEM; MICROFLUIDICS; MTS ASSAY; OVERALL SURVIVAL; PERSONALIZED MEDICINE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TUMOR BIOPSY; WART VIRUS;

EID: 85062479747     PISSN: None     EISSN: 20565623     Source Type: Journal    
DOI: 10.4155/fsoa-2016-0089     Document Type: Article

References (51)

1. McMahon S, Chen AY. Head and neck cancer. Cancer Metastasis Rev. 22, 21-24 (2003).
2. Louie KS, Mehanna H, Sasieni P. Trends in head and neck cancers in England from 1995 to 2011 and projections up to 2025. Oral Oncol. 51(4), 341-418 (2015).
3. Dobrossy L. Epidemiology of head and neck cancer: magnitude of the problem. Cancer Metastasis Rev. 24(1), 9-17 (2005).
4. Marur S, Forastiere AA, Torre LA et al. Head and neck squamous cell carcinoma: update on epidemiology, diagnosis, and treatment. Mayo Clin. Proc. 91(3), 386-396 (2016).
5. De Neve W, De Gersem W, Madani I. Rational use of intensity-modulated radiation therapy: the importance of clinical outcome. Semin. Radiat. Oncol. 22(1), 40-49 (2012).
6. Ghosh-Laskar S, Yathiraj PH, Dutta D et al. Prospective randomized controlled trial to compare 3-dimensional conformal radiotherapy to intensity-modulated radiotherapy in head and neck squamous cell carcinoma: long-term results. Head Neck. 38(S1), E1481-E1487 (2016).
7. Perri F, Pacelli R, Della Vittoria Scarpati G et al. Radioresistance in head and neck squamous cell carcinoma: biological bases and therapeutic implications. Head Neck. 37(5), 763-770 (2015).
8. Akervall J, Nandalur S, Zhang J et al. A novel panel of biomarkers predicts radioresistance in patients with squamous cell carcinoma of the head and neck. Eur. J. Cancer 50(3), 570-581 (2014).
9. Suh Y, Amelio I, Guerrero Urbano T, Tavassoli M. Clinical update on cancer: molecular oncology of head and neck cancer. Cell Death Dis. 5(1), e1018 (2014).
10. Echarri M, Lopez-Martin A, Hitt R. Targeted therapy in locally advanced and recurrent/metastatic head and neck squamous cell carcinoma (LA-R/M HNSCC). Cancers (Basel). 8(3), 27 (2016).
11. Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 354(6), 567-578 (2006).
12. Morris LGT, Chandramohan R, West L et al. The molecular landscape of recurrent and metastatic head and neck cancers. JAMA Oncol. 46(2), 114-117 (2016).
13. Lassen P, Eriksen JG, Krogdahl A et al. The influence of HPV-associated p16-expression on accelerated fractionated radiotherapy in head and neck cancer: evaluation of the randomised DAHANCA 6&7 trial. Radiother. Oncol. 100(1), 49-55 (2011).
14. Ziemann F, Arenz A, Preising S et al. Increased sensitivity of HPV-positive head and neck cancer cell lines to x-irradiation ± Cisplatin due to decreased expression of E6 and E7 oncoproteins and enhanced apoptosis. Am. J. Cancer Res. 5(3), 1017-1031 (2015).
15. Friedman JM, Stavas MJ, Cmelak AJ. Clinical and scientific impact of human papillomavirus on head and neck cancer. World J. Clin. Oncol. 5(4), 781-791 (2014).
16. Hickman JA, Graeser R, de Hoogt R et al. Three-dimensional models of cancer for pharmacology and cancer cell biology: capturing tumor complexity in vitro/ex vivo. Biotechnol. J. 9(9), 1115-1128 (2014).
17. Kim S-A, Lee EK, Kuh H-J. Co-culture of 3D tumor spheroids with fibroblasts as a model for epithelial-mesenchymal transition in vitro. Exp. Cell Res. 335(2), 187-196 (2015).
18. Stebbing J, Paz K, Schwartz GK et al. Patient-derived xenografts for individualized care in advanced sarcoma. Cancer 120(13), 2006-2015 (2014).
19. Dawson A, Green V, Bower R, Greenman J. Microfluidics: towards personalised medicine in cancer therapy. Drug Target Rev. 3, 12-17 (2016).
20. Whitesides GM. The origins and the future of microfluidics. Nature 442(7101), 368-373 (2006).
21. Avila K, Moxey D, de Lozar A, Avila M, Barkley D, Hof B. The onset of turbulence in pipe flow. Science 333(6039), 192-196 (2011).
22. Huang M, Fan S, Xing W, Liu C. Microfluidic cell culture system studies and computational fluid dynamics. Math. Comput. Model. 52(11), 2036-2042 (2010).
23. Passeraub PA, Almeida AC, Thakor NV. Design, microfabrication and analysis of a microfluidic chamber for the perfusion of brain tissue slices. Biomed. Microdevices. 5(2), 147-155 (2003).
24. Komeya M, Kimura H, Nakamura H et al. Long-term ex vivo maintenance of testis tissues producing fertile sperm in a microfluidic device. Sci. Rep. 6, 21472 (2016).
25. Dodson KH, Echevarria FD, Li D, Sappington RM, Edd JF. Retina-on-a-chip: a microfluidic platform for point access signaling studies. Biomed. Microdevices. 17(6), 114 (2015).
26. Yasotharan S, Pinto S, Sled JG, Bolz S-S, Günther A. Artery-on-a-chip platform for automated, multimodal assessment of cerebral blood vessel structure and function. Lab Chip 15(12), 2660-2669 (2015).
27. Chang TC, Mikheev AM, Huynh W, Monnat RJ, Rostomily RC, Folch A. Parallel microfluidic chemosensitivity testing on individual slice cultures. Lab Chip 14(23), 4540-4551 (2014).
28. Silva PN, Green BJ, Altamentova SM, Rocheleau JV. A microfluidic device designed to induce media flow throughout pancreatic islets while limiting shear-induced damage. Lab Chip 13(22), 4374-4384 (2013).
29. van Midwoud PM, Merema MT, Verpoorte E, Groothuis GMM. Microfluidics enables small-scale tissue-based drug metabolism studies with scarce human tissue. J. Lab. Autom. 16(6), 468-476 (2011).
30. Dawson A, Dyer C, Macfie J et al. A microfluidic chip based model for the study of full thickness human intestinal tissue using dual flow. Biomicrofluidics 10(6), 64101 (2016).
31. Astolfi M, Péant B, Lateef MA et al. Micro-dissected tumor tissues on chip: an ex vivo method for drug testing and personalized therapy. Lab Chip 16(2), 312-325 (2015).
32. Zambon A, Zoso A, Gagliano O et al. High temporal resolution detection of patient-specific glucose uptake from human ex vivo adipose tissue on-chip. Anal. Chem. 87(13), 6535-6543 (2015).
33. Carr SD, Green VL, Stafford ND, Greenman J. Analysis of radiation-induced cell death in head and neck squamous cell carcinoma and rat liver maintained in microfluidic devices. Otolaryngol. Head Neck Surg. 150(1), 73-80 (2014).
34. Ataç B, Wagner I, Horland R et al. Skin and hair on-a-chip: in vitro skin models versus ex vivo tissue maintenance with dynamic perfusion. Lab Chip 13(18), 3555 (2013).
35. Sylvester DC, Hattersley SM, Stafford ND, Haswell SJ, Greenman J. Development of microfluidic-based analytical methodology for studying the effects of chemotherapy agents on cancer tissue. Curr. Anal. Chem. 9(1), 2-8 (2013).
36. McCreedy T. Rapid prototyping of glass and PDMS microstructures for micro total analytical systems and micro chemical reactors by microfabrication in the general laboratory. Anal. Chim. Acta 427(1), 39-43 (2001).
37. Morrison FA. An Introduction to Fluid Mechanics. Cambridge University Press, UK (2013).
38. Hattersley SM, Dyer CE, Greenman J, Haswell SJ. Development of a microfluidic device for the maintenance and interrogation of viable tissue biopsies. Lab Chip 8(11), 1842-1846 (2008).
39. Hattersley SM, Sylvester DC, Dyer CE, Stafford ND, Haswell SJ, Greenman J. A microfluidic system for testing the responses of head and neck squamous cell carcinoma tissue biopsies to treatment with chemotherapy drugs. Ann. Biomed. Eng. 40(6), 1277-1288 (2012).
40. Engelholm SA, Spang-Thomsen M, Brünner N, NØhr I, VindelØv LL. Disaggregation of human solid tumours by combined mechanical and enzymatic methods. Br. J. Cancer 51(1), 93-98 (1985).
41. Burrell RA, McGranahan N, Bartek J, Swanton C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature 501(7467), 338-345 (2013).
42. Pedicini P, Nappi A, Strigari L et al. Correlation between EGFR expression and accelerated proliferation during radiotherapy of head and neck squamous cell carcinoma. Radiat. Oncol. 7(1), 143 (2012).
43. Ledgerwood LG, Kumar D, Eterovic AK et al. The degree of intratumor mutational heterogeneity varies by primary tumor sub-site. Oncotarget 7(19), 27185-27198 (2016).
44. Rocco JW. Mutant Allele Tumor Heterogeneity (MATH) and head and neck squamous cell carcinoma. Head Neck Pathol. 9(1), 1-5 (2015).
45. Ma C, Zhao L, Zhou E-M, Xu J, Shen S, Wang J. On-chip construction of liver lobule-like microtissue and its application for adverse drug reaction assay. Anal. Chem. 88(3), 1719-1727 (2016).
46. Kim HJ, Ingber DE. Gut-on-a-chip microenvironment induces human intestinal cells to undergo villus differentiation. Integr. Biol. (Camb). 5(9), 1130-1140 (2013).
47. Ruppen J, Wildhaber FD, Strub C et al. Towards personalized medicine: chemosensitivity assays of patient lung cancer cell spheroids in a perfused microfluidic platform. Lab Chip 15(14), 3076-3085 (2015).
48. Sabhachandani P, Motwani V, Cohen N, Sarkar S, Torchilin V, Konry T. Generation and functional assessment of 3D multicellular spheroids in droplet based microfluidics platform. Lab Chip 16(3), 497-505 (2016).
49. Smith R. Chemical Process Design and Integration. Wiley, Chichester, UK (2014).
50. Brody JP, Yager P, Goldstein RE, Austin RH. Biotechnology at low Reynolds numbers. Biophys. J. 71, 3430-3441 (1996).
51. Brana I, Siu LL. Locally advanced head and neck squamous cell cancer: treatment choice based on risk factors and optimizing drug prescription. Ann. Oncol. 23(Suppl. 10), 178-185 (2012).